Get the Stockscreener App
450.41
0.58%
-2.65
After Hours:
448.00
-2.41
-0.54%
Vertex Pharmaceuticals Inc stock is traded at $450.41, with a volume of 1.08M.
It is down -0.58% in the last 24 hours and up +1.38% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$453.06
Open:
$453.64
24h Volume:
1.08M
Relative Volume:
0.81
Market Cap:
$114.32B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
26.70
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+5.98%
1M Performance:
+1.38%
6M Performance:
+3.03%
1Y Performance:
+6.95%
1-Day Range:
$447.36
$456.68
1-Week Range:
$421.11
$456.68
52-Week Range:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals stock (US92532F1003): Shareholder approval fuels biotech momentum - AD HOC NEWS
Vertex Pharma stock (US92532F1003): Shares up 1.06% to $453 amid biotech strength - AD HOC NEWS
Vertex Pharmaceuticals (VRTX) Announces Approval of 2026 Stock a - GuruFocus
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharma stock (US92532F1003): Rockets 3.77% on strong options volume - AD HOC NEWS
Carmen Bozic sells 2,329 VRTX shares on 02/27, 03/13 and 03/27 (VRTX) - Stock Titan
Why is Vertex Pharmaceuticals stock rallying today? - Investing.com
Why is Vertex Pharmaceuticals stock rallying today? By Investing.com - Investing.com Canada
Vertex Pharma stock (US92532F1003): Earnings highlight pain drug advances - AD HOC NEWS
Vertex’s Germany CASGEVY Deal Highlights Growing Non CF Growth Story - Yahoo Finance
A year after Vertex’s big launch, pain drug research faces a pivotal moment - BioPharma Dive
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? - The Motley Fool
Vertex to Participate in Upcoming May Investor Conferences - Business Wire
Vertex Pharma stock (US92532F1003): Latest developments and business overview - AD HOC NEWS
Top Biotech Stocks To ConsiderMay 10th - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) Latest Stock News & Headlines - Yahoo Finance
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know - MSN
Biotech Stocks To Watch NowMay 9th - MarketBeat
Vertex Pharma stock (US92532F1003): Q1 2026 earnings beat lifts shares on growth in new disease area - AD HOC NEWS
Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines - TipRanks
Vertex Pharmaceuticals Q2 2026 earnings preview - MSN
Vertex Pharmaceuticals (NQ: VRTX - FinancialContent
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings - Yahoo Finance
Vertex Pharma stock (US92532F1003): Mixed Q1 results and 2026 guidance reiterated - AD HOC NEWS
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Secures Reimbursement Agreement fo - GuruFocus
April 2026 — CDMO Opportunities And Threats Report - Bioprocess Online
Vertex's New Big Pharma Partners - Yahoo
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 OutlookNews and Statistics - IndexBox
VRTX Technical Analysis | Trend, Signals & Chart Patterns | VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) - ChartMill
Vertex (VRTX) Q1 2026 Earnings Call Transcript - AOL.com
Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Vertex Pharmaceuticals (NASDAQ: VRTX) affiliate proposes stock sales; insider sales listed - Stock Titan
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy (VRTX) - Seeking Alpha
Michel Lagarde At Vertex Pharmaceuticals Acquires Stock Options Worth $9K - Benzinga
BRUCE SACHS Backs Up Beliefs With A Notable Acquisition Of Vertex Pharmaceuticals Stock Options Worth $9K - Benzinga
Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth - Sahm
German reimbursement deal for Vertex’ Casgevy - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC) - The Globe and Mail
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany - BioSpace
Vertex secures German reimbursement deal for gene therapy By Investing.com - Investing.com Canada
Vertex secures German reimbursement deal for gene therapy - Investing.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and Merck & Company (MRK) - The Globe and Mail
Germany backs access to Vertex's one-time gene therapy for blood disorders - Stock Titan
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness - Yahoo Finance
Vertex Pharmaceuticals: Investment Returns and Future Outlook - Intellectia AI
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Vertex Pharmaceuticals Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VRTX) 2026-05-06 - Seeking Alpha
Insider Sell: Sangeeta Bhatia Sells Shares of Vertex Pharmaceuti - GuruFocus
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
2.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):